Skip to main content

Prediction of cytotoxic drug concentrations occurring on the day of autologous stem cell rescue during a high-dose chemotherapy regimen.

Abstract: In a clinical study a high-dose chemotherapy (HDCT) regimen was investigated as a treatment option in germ cell cancer patients who did not benefit from one or multiple cycles of conventional chemotherapy. The therapy regimen comprised a combination of carboplatin, etoposide and thiotepa in total doses of up to 1,500, 2,400 and 750 mg/m2, respectively, and a myelosupportive treatment comprising an autologous stem cell rescue (ASCR) retransfusing with retransfusion of CD34+ cells on day seven of the HDCT and administration of granulocyte colony-stimulating factor starting on day eight. The objective of this population pharmacokinetic analysis was the pharmacokinetic (PK) characterization of the three cytotoxic drugs in the setting of HDCT and the assessment of the remaining cytotoxic drug concentrations on the day of the ASCR.

Full Reference: Nock, Valerie, Andreas Lindauer, Ulrich Jaehde, and Charlotte Kloft. “Prediction of Cytotoxic Drug Concentrations Occurring on the Day of Autologous Stem Cell Rescue during a High-Dose Chemotherapy Regimen.” International Journal of Clinical Pharmacology and Therapeutics 51, no. 1 (January 2013): 38–40.

Link to full text:

How can we help you?